At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a
In Brief
A clinical study evaluating Genetic Risk Score: Number Format, Genetic Risk Score: Number + Pictograph, and 2 other interventions for Prostate Cancer and 2 related conditions. Completed, enrolled 700 participants.
Detailed Summary
This study was designed to compare the efficacy, perception, decision making, and cost-effectiveness of genomic and non-genomic approaches for risk assessment of prostate cancer and for chemoprevention of prostate cancer.
Study Details
Timeline
Interventions
Genetic Risk Score: Number + Pictograph Genetic risk score based on validated panel of 46 single nucleotide polymorphisms previously identified to be associated with Prostate Cancer risk by Genome Wide Association Studies, presented to subjects as a number.
Genetic Risk Score: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
Family History: Number Format Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
Family History: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.